Abstract Chemotherapy-induced nausea and vomiting is one of the most worrisome adverse effects of chemotherapy for cancer patients. It can cause severe discomfort and affect the quality of life. In recent years, the incorporation of new drugs has increased the efficacy of antiemetic treatments in the control of emesis associated with chemotherapy. This guideline, in which we give some treatment recommendations with level of evidence and grade of recommendation, provides an update of the previously published guideline of the Spanish Society of Medical Oncology and represents our continued commitment to improving supportive care in cancer patients.
consumption, the presence of emesis in previous chemotherapy treatments, anticipatory emesis, and psychological disorders, such as anxiety. Likewise, dehydration and metabolic disorders such as hyperkalemia, concurrent treatments (opioids, antibiotics, antifungals, etc.), and a history of motion sickness or hyperemesis gravidarum may increase the likelihood of emesis. Furthermore, certain polymorphisms of the enzymes that metabolize 5-HT3 receptor antagonists and of the receptor itself are associated with a greater risk of emesis [3] . Knowing these factors makes it possible to adapt antiemetic treatment to each patient, especially in the presence of more than one of the aforenamed factors.
The classification of emetogenic potential of cytostatics encompasses four categories: high, moderate, low, and minimal. However, it must be noted that a significant number of patients receive treatments consisting of a combination of several cytostatic drugs instead of monotherapy. One of the issues to be resolved is how to gauge the emetogenic potential of the said combinations ( Table 1) .
The recent years have witnessed the introduction of new molecules that have improved the control of chemotherapy-induced emesis. For this reason, the Spanish Society of Medical Oncology (SEOM) believes that the time has come to review and update the previous Clinical Guidelines published in 2010 [6] to include new developments.
Guideline methods
Under the auspices of the Spanish Society of Medical Oncology (SEOM), a number of experts in the field together with two coordinators were designated to develop these evidence-based, clinical practice guidelines. Recommendations and evidence have been graded, based on the guideline development recommendations [7] .
Diagnosis
Four types of CINV can be defined: acute, delayed, anticipatory, and incidental episodic emesis [8] .
• Acute emesis occurs within the first 24 h following chemotherapy infusion, most often between 2 and 6 h post-infusion.
• Delayed emesis occurs 24 h after chemotherapy is administered. It most typically ensues between 48 and 72 h and is generally associated with drugs such as cisplatin, carboplatin, cyclophosphamide, and anthracyclines.
• Anticipatory emesis develops during the hours prior to receiving cytostatic treatment.
• Incidental episodic emesis appears more than 120 h after receiving chemotherapy. 
Treatment
The treatment of chemotherapy-associated emesis is based on drugs that inhibit or antagonize signaling of some of the neurotransmitters involved in the process. The drugs used in antiemetic prophylaxis can be divided as:
• The classical antiemetic agents, prior to the 1990s, are gradually losing relevance, although they can still be very useful in specific situations, such as refractory emesis, or when modern agents or steroids are contraindicated. These drugs are dopaminergic receptor (subtype D2) antagonists and include phenothiazine (proclorpromacine, perphenazine, and tietilperacilin), butyrophenones, (haloperidol and droperidol), and substituted benzamides (metoclopramide, domperidone, and alizapride) [9] .
• Introduced in the early 1990s, competitive serotonergic receptor (5-Hydroxytryptamine-3 or 5-HT 3 subtype) antagonists are the reference antiemetic drugs since then. First-generation 5-HT3 receptor antagonists include ondansetron, granisetron, dolasetron, tropisetron, and second-generation agents in this class include palonosetron. First-generation drugs have similar efficacy that increases when administered with steroids. Ondansetron should not be used in patients with congenital prolonged QT-interval syndrome and should be monitored in patients with electrolyte abnormalities, congestive heart failure, bradyarrhythmias or when other drugs that may prolong the QT interval are administered. Palonosetron has demonstrated greater efficacy than first-generation setrons in phase III trials; it produces a long-lasting serotonin receptor blockade, and has synergistic activity with neurokinin inhibitors [10] .
• Substance P antagonists (of the neurokinine-1 receptor, NK-1): aprepitant, fosaprepitant, netupitant, rolapitant.
In combination with 5-HT3 receptor antagonists and steroids, they offer better control in acute and delayed emesis in highly emetogenic chemotherapy regimens [11, 12] .
• Steroids: dexamethasone, methylprednisolone. Their mechanism of action is unknown, although it is probably related to the inhibition of prostaglandin synthesis and there is ample scientific evidence that supports their use. The most widely used drug in this class is dexamethasone, which offers great efficacy when used either in monotherapy or in combination.
• Benzodiazepines: lorazepam, alprazolam, midazolam, and olanzapine (a thienobenzodiazepine with antipsychotic effects, which enhances the antiemetic effect, especially in delayed nausea [13] .
• Cannabinoids (dronabinol, nabilone): They can provide an antiemetic effect in patients who do not respond to 5-HT3 receptor antagonists and NK-1 receptors and in the prevention of anticipatory emesis.
The combination of the different drugs, as stated in the guidelines, allows for antiemetic therapy to be adapted to each patient and clinical situation:
1. Prophylactic antiemetics in treatments with high emetogenic potential [12] [13] [14] : Highly emetogenic chemotherapy is considered to be those agents or schedules that would cause vomiting in more than 90% of the cases in the absence of antiemetic prophylaxis. Administration of these drugs after chemotherapy is not recommended because it has not proven to be beneficial and they have associated side effects.
(ii) There are currently several neurokinine-1 receptor inhibitors to choose from: aprepitant (orally at a dose of 125 mg on day 1 and 80 mg on days 2 and 3) or fosaprepitant (150 mg iv) on day 1. Netupitant is a second-generation NK1 receptor antagonist that targets the serotonin and substance P-mediated pathways involved predominantly in delayed emesis. 3. Prophylactic antiemetics in treatments with low and minimal emetogenic potential [19] : Drugs associated with low emetic potential are those for which the risk of emesis lies between 10 and 30%. For drugs having a minimal emetic potential, the risk is \10%. Most new-targeted agents are included in this category. (i) The general principle is to adjust the regimen to be used for a higher risk group. Some patients may require new agents with different mechanisms of action (i.e. lorazepam, alprazolam, olanzapine, prochlorperazine, or haloperidol). Olanzapine has shown superiority over metroclopramide in a recent randomized trial.
5. Prevention of anticipatory nausea and vomiting [20] :
Anticipatory nausea and vomiting is usually due to a learned response to chemotherapy, and increases with each subsequent cycle. Many individual factors such as age \50 years, anxiety, nausea, and vomiting after the previous chemotherapy treatment may predict the appearance of anticipatory nausea and vomiting. 6. Prevention of radiotherapy-induced nausea and vomiting [21] :
The emetic risk of radiotherapy is divided into four risk levels: high, moderate, low, and minimal. These levels depend on the site of radiation and do not take into account radiation dose, fractionation, or technique, or other proposed risk factors. 
